Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Nov 12, 2014	Biocept Launches Lung Cancer Offering Blood-Based Liquid Biopsy Testing Launched for NSCLC Indications	View HTML Biocept Launches Lung Cancer Offering 17 KB
Toggle Summary Nov 13, 2014	Biocept Reports Third Quarter 2014 Financial Results SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30,	View HTML Biocept Reports Third Quarter 2014 Financial Results 25.3 KB
Toggle Summary Dec 3, 2014	Biocept Appoints Experienced Physician as Medical Director Veena Singh, MD, FCAP, FACMG Brings Years of Medical Experience to Biocept Team	View HTML Biocept Appoints Experienced Physician as Medical Director 23.6 KB
Toggle Summary Dec 15, 2014	Biocept Expands Worldwide Microchannel Patent Protection to South Korea Korean Patent Includes Microfluidic Channel for Capturing Circulating Tumor Cells	View HTML Biocept Expands Worldwide Microchannel Patent Protection to South Korea 23.1 KB
Toggle Summary Dec 17, 2014	Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells Biocept's CTC Test Identified Approximately 22 Percent of Women With Breast Cancer to Have HER2 Positive CTC After Disease Progression Following a HER2 Negative Diagnosis With Solid Tumor Biopsy	View HTML Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells 13.2 KB
Toggle Summary Jan 7, 2015	Biocept to Present at the 8th Annual OneMedForum SAN DIEGO, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to	View HTML Biocept to Present at the 8th Annual OneMedForum 9 KB
Toggle Summary Jan 7, 2015	Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network ACPN's Approximately 19 Million Participants Now Have Access to Biocept's Suite of Blood-Based Diagnostics	View HTML Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network 9 KB
Toggle Summary Jan 8, 2015	Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment Companies to Evaluate Expression and Mutation in NSCLC Therapeutic Target ALK	View HTML Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment 25.5 KB
Toggle Summary Jan 12, 2015	Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients Blood-Based Liquid Biopsy Technology Launched for Testing Regions of the EGFR Gene Associated With Acquired Resistance in NSCLC Indications	View HTML Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients 23.7 KB
Toggle Summary Jan 20, 2015	Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer Company launches blood-based 'liquid biopsy' to identify ROS1 rearrangement and better inform NSCLC treatment decisions	View HTML Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer 16.8 KB

Investor Relations

Press Releases

Contact Biocept, Inc.